Condition: Esophageal Neoplasms · Esophageal Diseases · Digestive System Neoplasms · Sponsor: Fujian Cancer Hospital
This is a prospective single-arm exploratory clinical study. The efficacy and safety of camrelizumab combined with chemoradiotherapy and camrelizumab combined with chemotherapy were evaluated in patients with advanced esophageal cancer who had not previously received any systemic antitumor therapy for esophageal cancer.
This description comes directly from the study's public registry record.
Jiancheng Li, Doctor · 13906900190 · jianchengli6@126.com
Always discuss trial participation with your own doctor first.
| Fujian Cancer Hospital | Fuzhou, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05624099